Credit: Shutterstock photoCara Therapeutics, a Phase 3-stage biotech developing a novel opioid pain medication, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Cara Therapeutics plans to list on the NASDAQ under the symbol CARA. Cara Therapeutics initially filed confidentially on 10/4/2013. Stifel and Piper Jaffray acted as joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
